Belimumab for the treatment of systemic lupus erythematosus. - Wikidata - awgldk - TriplyDB

Belimumab for the treatment of systemic lupus erythematosus.

Belimumab for the treatment of systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34455827

about

BAFF level increased in patients with autoimmune hemolytic anemia.Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23.CD40 Signaling in Graves Disease Is Mediated Through Canonical and Noncanonical Thyroidal Nuclear Factor κB Activation.The use of biologics in pregnant patients with rheumatic disease.Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance.Effect of infusion of monoclonal antibodies to tumour necrosis factor-receptor super family 25 on graft rejection in allo-immune mice receiving autologous marrow transplantation.

P2860

Q35643768-16189161-236A-4A7C-B4CA-22E50BCA0350 Q36106681-88EA39EB-18E7-4AE1-AF58-81ECA57F007F Q38604547-C0B658A6-3027-4334-9B4D-4502B4D2258F Q38690844-A6435821-43D4-43D4-A63F-C745F1F544CE Q38744431-0C6481AE-5C9F-4326-9D5B-FDEA6574CB72 Q39120292-5E0F4145-F15C-4CFB-850F-482CAE088504 Q39192359-11E6A68C-D23A-4203-A6BC-BE5ADCE60CBC Q50438780-1FEB2102-5A98-415A-B8B0-E0F8C8CBB20E Q51320634-83AEC668-BA1C-49E1-BD6D-1AA5B56938A7

P2860

Belimumab for the treatment of systemic lupus erythematosus.

http://www.wikidata.org/entity/Q34455827

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Belimumab for the treatment of systemic lupus erythematosus.

@ast

Belimumab for the treatment of systemic lupus erythematosus.

@en

Belimumab for the treatment of systemic lupus erythematosus.

@nl

type

label

Belimumab for the treatment of systemic lupus erythematosus.

@ast

Belimumab for the treatment of systemic lupus erythematosus.

@en

Belimumab for the treatment of systemic lupus erythematosus.

@nl

prefLabel

Belimumab for the treatment of systemic lupus erythematosus.

@ast

Belimumab for the treatment of systemic lupus erythematosus.

@en

Belimumab for the treatment of systemic lupus erythematosus.

@nl

P1433

Q34455827-4C6D90E3-28A7-43D0-90E2-02F85276F35E

P1476

Q34455827-55205B69-FE7D-43E5-9130-483206EE26FC

P2093

Q34455827-6CCEDE1A-CD9D-444F-8116-2D47CB2E9DB9

Q34455827-850EA050-9088-41BD-8DF0-89E06090BF46

P2860

Q34455827-0B70C895-8FAA-4A9E-ACE8-6609BA37F5A8

Q34455827-0E75355B-8556-4748-ABF1-DAA27221ECDE

Q34455827-180D7422-9DD6-4B3E-B573-E4516F3166E0

Q34455827-22725D10-68F5-487E-9115-A270B1B864F9

Q34455827-260CB85B-697F-4ABF-8CB7-B88615766C7D

Q34455827-2A310F72-A3A2-4C86-AF99-A1E568C94CE1

Q34455827-34C5F071-8E48-432E-B8EF-E4D72B7AE780

Q34455827-3A81871D-E0AB-4066-8C09-E33DF55F2ACB

Q34455827-3E69ACF5-7A9E-4904-BA94-F19FD0A78D73

Q34455827-45C67699-7432-47DE-A357-E09C2ECBE015

P304

Q34455827-3A51D251-53FA-4D23-A142-5C3E2B4DB8A4

P31

Q34455827-E7E1D0C5-5FD2-4BC1-AAB0-97F756F0204F

P356

Q34455827-63D32821-07F4-40C3-8CEA-E95B3C67824F

P433

Q34455827-806CD8B1-1664-4A1E-BD8C-D2478FF57DBE

P478

Q34455827-A63353FE-481B-4520-9EA1-4244D8A1079C

P577

Q34455827-E68FBED0-7B35-4B7F-8CA8-10E94B661995

P698

Q34455827-38D27DC5-FC07-4F69-91B6-EFC8D76D9961

P356

1744666X.2015.996550

P1433

Expert Review of Clinical Immunology

P1476

Belimumab for the treatment of systemic lupus erythematosus.

@en

P2093

David P D'Cruz

http://www.w3.org/2001/XMLSchema#string

Natasha Jordan

http://www.w3.org/2001/XMLSchema#string

P2860

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

P304

195-204

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.2015.996550

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25543845

http://www.w3.org/2001/XMLSchema#string